Introduction

Silicone breast implants often contain pyrogenic amorphic nano silica, sometimes treated with trimethylsilyl groups, as filler to improve mechanical properties. Although silicone polymers have been extensively investigated, there is little attention to the long-term effects of nano silica, especially after degradation in the body. Based on available scientific literature, it is suggested that pyrogenic nano silica may cause a pro-inflammatory response, activate T-cells and potentially contribute to Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL), a rare T-cell lymphoma, and other symptoms such as Breast Implant Illness (BII). This summary presents the main findings and stresses the need for further research.

Important findings from the literature

1. Toxicity of pyrogenic nano silica to macrophages:
   • Zhang et al. (2012) suggest that pyrogenic amorphic silica (fumed silica) may be more toxic to macrophages than crystalline silica (such as Min-U-Sil), by three rings (3MRs), high concentration of isolated silanol groups, and chain-like aggregates, which may cause membrane disturbance. Pyrogenic silica appears to activate the NLRP3 inflammasome, which can lead to IL-1β secretion, erythrocyte hemolysis, and cell death. Thermal treatment may reduce toxicity by silanol reduction, while hydration may partially restore toxicity, which is relevant to implant degradation. Further study is needed to confirm these effects. (Source: Zhang, H., et al., 2012, Journal of the American Chemical Society).
   • Davies et al. (ASTM STP 732) found that pyrogenic silica and micronized silica gels may be as cytotoxic to macrophages as crystalline silica, due to lysosomal damage and oxidative stress. This suggests that pyrogenic silica can be pathogen after prolonged exposure, such as in implants, but more in vivo studies are needed. (Source: Davies, R., et al., ASTM STP 732, (Effects of Synthetic Silicones on Mouse Peritoneal Macrophages In Vitro).
2. Possible association with lymphomas in animal studies:
   • IARC Monograph 68 (1997) reports that crystalline silica in experimental animals caused lymphomas, originally called histiocytic lymphoma, but later classified as anaplastic large cell lymphoma (ALCL). This suggests that silica is possible T-cell malignancies can be stimulated by chronic immune stimulation. Monograph 68 treats pyrogenic silica limited, but evidence of toxicity suggests that similar effects are possible. (Source: IARC Monograph 68, 1997).
3. Potential T-cell activation and CD30 expression:
   • The Rat Genome Database reports that silicon dioxide increases the expression of TNFRSF8 mRNA (coding for CD30) in rats. CD30 is a marker for activated T-cells and a characteristic of BIA-ALCL, suggesting a possible role of silica in T-cell activation. (Source: Rat Genome Database).
4. Possible synergy with biofilms and LPS:
   • Biofilms on textured implants, often with gram-negative bacteria such as Ralstonia spp., produce lipo polysaccharide (LPS), which can activate TLR4 and enhance cytokine production. The combination of pyrogenic silica and LPS may enhance a pro-inflammatory response, which activates T cells and promotes CD30 inhibition.
5. Degradation of trimethylsilyl-treated silica:
   • Trimethylsilyl-treated pyrogenic nano silica, used in silicone implants, has a hydrophobic surface that may reduce toxicity by masking silanol groups. Degradation (by aging, oxidation, or body fluids) may result in loss of coating, exposing silanol groups and potentially increasing toxicity, similar to untreated pyrogenic silica. Zhang et al. suggest that surface modifications affect toxicity, but specific effects of TMS treatment require further studies.

Hypothesis: Potential contribution to BIA-ALCL

The literature suggests that trimethylsilyl-treated pyrogenic nano silica, after degradation from silicone breast implants, may cause a pro-inflammatory response that activates T-cells and can potentially contribute to BIA-ALCL. This could be done through:

1. Macrophage toxicity: Released nano silica can damage macrophages, potentially leading to NLRP3 activation, ROS production, and IL-1β secretion, resulting in chronic inflammation.
2. Possible synergy with LPS: LPS from biofilms may enhance the immune response via TLR4, which promotes antigen presentation and cytokine production.
3. T-cell activation: The pro-inflammatory microenvironment can activate T cells, potentially leading to CD30 overregulation.
4. Possible lymphomaogenesis: Chronic T-cell stimulation, possibly in combination with genetic/ epigenetic changes, may contribute to CD30-positive, ALK-negative BIA-ALCL.

In addition, nano silica may contribute to Breast Implant Illness (BII) due to systemic inflammation reactions.

Lacunes and ethical concerns

• Lack of specific studies: There are no direct studies of trimethylsilyl-treated nano silica in implants despite evidence of pyrogenic silica toxicity.
• Underestimate of additives: Manufacturers and regulators focus on silicone polymers, not additives such as nano silica, which are rarely mentioned.
• Insufficient post-market surveillance: Long-term effects are not systematically investigated, which may result in patients at risk.
• Lack of transparency: Patients and doctors are often unaware of nano silica, which undermines informed consent.

Conclusion

The literature suggests that pyrogenic nano silica, after degradation of silicone breast implants, may cause a pro-inflammatory response that activates T-cells and can potentially contribute to BIA-ALCL and BII. The toxicity of pyrogenic silica to macrophages, possible association with ALCL in animal studies, and increased CD30 expression support this hypothesis. Possible synergy with LPS from biofilms can enhance these effects. The lack of research into nano silica in implants is a serious gap, which requires urgent attention.

Recommendations

1. Research: Stimulate immunotoxicity and potential carcinogenic effects of trimethylsilyl-treated nano silica in implants.
2. Transparency: Mandatory manufacturers to specify and test all components of implants.
3. Post market surveillance: Implement systematic follow-up of implant patients.
4. Patient information: Inform patients about possible risk derivatives of additives.

Sources

• Zhang, H., et al. (2012). Processing pathway dependence of amorphous silica nanoparticle toxicity: colloidal vs pyrolytic. Journal of the American Chemical Society.
• Davies, R., et al. (ASTM STP 732). Health Effects of Synthetic Silicone Particles.
• IARC Monograph 68 (1997). Silicone, Some Silices, Coal Dust and Para-Aramid Fibrils.
• Rat Genome Database (data on TNFRSF8 mRNA expression).

^{Disclaimer:
The information on this website is intended for informational purposes and is based on carefully collected scientific research. The topics and hypotheses discussed have not yet been widely recognised within the medical community. We are not doctors and do not give medical or legal advice. No rights can be derived from the content of this website. Stichting SVS accepts no liability for any consequences, damage, complaints or legal proceedings arising from the use of this information.}